Mit Magzter GOLD unbegrenztes Potenzial nutzen

Erhalten Sie unbegrenzten Zugriff auf über 9.000 Zeitschriften, Zeitungen und Premium-Artikel für nur

$149.99

$74.99/Jahr

Versuchen GOLD - Frei

Mit Magzter GOLD unbegrenztes Potenzial nutzen

Erhalten Sie unbegrenzten Zugriff auf über 9.000 Zeitschriften, Zeitungen und Premium-Artikel für nur

$NaN

$NaN/Jahr

Beeilen Sie sich, das Angebot ist zeitlich begrenzt!

Std

Minuten

Sekunden

Bio Spectrum - March 2026

Mit Magzter GOLD unbegrenztes Potenzial nutzen

Lesen Bio Spectrum zusammen mit über 9.000 anderen Zeitschriften und Zeitungen mit nur einem Abonnement

Katalog anzeigen

1 Monat

$14.99

1 Jahr $149.99

$74.99

$6/month

Save 50%
Hurry, Offer Ends in 2 Days

Too Good To End! SALE Extended For

12 Hours

42 Mins

32 Secs

(OR)

Abonnieren Sie nur Bio Spectrum

Geschenk Bio Spectrum

Jederzeit kündbar.

(Keine Verpflichtungen) ⓘ

Sollten Sie mit Ihrem Abonnement nicht zufrieden sein, senden Sie uns innerhalb von 7 Tagen nach Abonnementbeginn eine E-Mail an help@magzter.com, um eine vollständige Rückerstattung zu erhalten. Versprochen! (Hinweis: Gilt nicht für den Kauf einzelner Ausgaben.)

Digitales Abonnement

Sofortiger Zugriff ⓘ

Abonnieren Sie jetzt, um sofort mit dem Lesen auf der Magzter-Website sowie in den iOS-, Android- und Amazon-Apps zu beginnen.

Verifiziert sicher

zahlen ⓘ

Magzter ist ein verifizierter Authorize.Net-Händler. Weitere Informationen

In dieser Ausgabe

Can India’s CDMOs Lead the Next Biopharma Wave?
India’s Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3–3.5 billion today to $22–25 billion by 2035, noted Boston Consulting Group (BCG). While small molecules continue to form the backbone of manufacturing, new opportunities are emerging in biologics, antibody drug conjugates (ADCs), gene therapies, and RNA therapeutics. As India gears up for this next phase of expansion, what challenges stand in the way, and how is the industry preparing to address them? Let’s find out.

Medicines or Margins? India's Drug Pricing Crossroads.

Pharmaceutical pricing in India lies at the crossroads of economics, ethics and public health.

2 mins

Govt launches first RDI Fund Call, inaugurates unique initiative of Innovation Financing

Dr Jitendra Singh, Minister of State with Independent Charge for Science & Technology, has launched the first Open Call of Technology Development Board (TDB) under the Research, Development and Innovation (RDI) Fund of the Anusandhan National Research Foundation (ANRF).

1 mins

Chhattisgarh eyes investments with highincentive policy and dedicated pharma park

Chhattisgarh government is stepping up efforts to position itself as a leading pharmaceutical and biotechnology hub in central India, backed by a high-incentive industrial policy, a dedicated pharma park at Nava Raipur and expanding healthcare and manufacturing infrastructure in the state.

1 mins

Health Ministry to reduce regulatory burden and promote ease of doing pharma business

In line with Prime Minister Narendra Modi's directions to reduce regulatory burden and promote ease of doing business, the Union Ministry of Health and Family Welfare has notified significant amendments to the New Drugs and Clinical Trials Rules, 2019.

1 mins

Centre revises Startup Recognition Framework to strengthen Startup India Action Plan

The government of India has revamped the Startup Recognition Framework to further strengthen the Startup India Action Plan and take forward the Prime Minister's vision of positioning India as a global innovation powerhouse, manufacturing-led economy and hub for emerging tech.

1 mins

Shukra Pharma receives YEIDA LOI for Rs 600 Cr facility to advance surgical robotics, cancer therapy

Shukra Pharmaceuticals has received a letter of intent (LoI) from the Yamuna Expressway Industrial Development Authority (YEIDA) for 10 acres of land in the Medical Device Park, Sector 28, Greater Noida, with a planned investment of approximately Rs 600 crore.

1 mins

Modern Diagnostic & Research Centre concludes IPO, raising Rs 36.89 Cr

Gurugram-based Modern Diagnostic & Research Centre, a leading diagnostic chain, has successfully concluded its Initial Public Offering (IPO), raising Rs 36.89 crore, which received an exceptional response from investors across categories.

1 mins

Wysa gets £5.3 M from Wellcome for digital mental health intervention study on adolescent girls in India

Wellcome has awarded £5.3 million to Bengaluru-based Wysa to fund a scale-up study that will adapt a clinically validated digital mental health intervention for adolescent girls living in rural India, a population facing some of the most significant mental health inequalities globally.

1 mins

BizDateUp acquires 5.88% stake in IOTA Diagnostic to scale at-home diagnostic solutions

Mumbai-based BizDateUp, an early-stage venture capital & investment firm focused on impact-led and scalable innovation, has invested an undisclosed amount for a 5.88 per cent stake in IOTA Diagnostic, a med-tech startup pioneering non-invasive, athome diagnostic solutions.

1 mins

Leeford Healthcare commits Rs 200 Cr for expansion of ortho & mobility aids division

Punjab-based Leeford Healthcare has announced a strategic investment of Rs 200 crore in the next three years to rapidly scale its Orthopaedic & Mobility Aids division, signalling a major push into India's fast-growing preventive healthcare and rehabilitation market.

1 mins

Kapiva launches Rs 50 Cr innovation fund to build future-ready ayurveda ecosystem

Bengaluru-based Kapiva, India's first modern holistic Ayurvedic brand for millennials, has announced the launch of the Kapiva Innovation Fund (KIF), a commitment of up to Rs 50 crore to support research and innovation in Ayurveda.

1 mins

Forus Health secures CDSCO approval for AI-led Diabetic Retinopathy screening tool

Bengaluru-based medtech firm Forus Health has received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) for its FH-POISE DRT (Diabetic Retinopathy Tools).

1 mins

MedGenome expands infectious disease testing portfolio with MetaSeq

Bengaluru-based MedGenome, India's leading genomics-driven diagnostics company, has announced the launch of MetaSeq, an advanced blood test designed to support faster and more comprehensive detection of bloodstream infections (BSI).

1 mins

ASI Telangana partners with Medtronic to train young surgeons

Medtronic, a global leader in medical technology, has signed a Memorandum of Understanding (MoU) with the Telangana State Chapter of the Association of Surgeons of India (ASI) to train residents, postgraduates, and early career surgeons in open and laparoscopy procedures using new-age technologies via collaborative skill-building training programmes.

1 mins

Zydus unveils world's first biosimilar of Nivolumab, 'Tishtha', in India to treat multiple cancers

Ahmedabad-based Zydus Lifesciences has launched the world's first biosimilar of Nivolumab in India under the brand name Tishtha, reinforcing the company's growing capability in advanced biologics and Immuno-Oncology.

1 mins

Novo Medi Sciences launches next-gen Varicella Vaccine built on advanced formulation

Mumbai-based Novo Medi Sciences (Novo Group) has announced the launch of NEXIPOX PLUS, the most recent innovation in Varicella vaccine in decades.

1 mins

Wipro GE Healthcare unveils Made-in-India, AI-powered breakthrough in MR imaging

Wipro GE Healthcare, a leading global medical technology, diagnostics, and digital solutions innovator, announced the launch of SIGNA Prime Elite, its latest MR imaging system, at the Indian Radiological and Imaging Association (IRIA) 2026 Annual Conference in Hyderabad.

1 mins

Can India's CDMOS Lead the Next Biopharma Wave?

India's Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3-3.5 billion today to $22-25 billion by 2035, noted Boston Consulting Group (BCG).

8 mins

"In the coming 5 years from now, no Indian CROS will grow or survive without the use of AI"

In January 2026, Ahmedabad-based Veeda Lifesciences announced a strategic leadership transition that marks a new chapter in the company's evolution.

5 mins

"Dependence on China for certain raw materials remains a vulnerability"

Jubilant Biosys - a Noida-based Contract Research, Development, and Manufacturing Organisation (CRDMO), a vertical of Jubilant Pharmova - operates across drug discovery services and the CDMO-API business, with a focus on integrated chemistry-led solutions that support programmes from early discovery through scale-up.

5 mins

India-EU FTA: Redefining the Pharma Growth Equation

On January 27, 2026, after years of negotiations, India and the European Union announced a landmark Free Trade Agreement.

4 mins

Budget 2026-27: Life Sciences Hits & Misses

The recently announced Union Budget 2026-27 by Finance Minister Nirmala Sitharaman has been welcomed as a positive step for the sector at a time when India's life sciences industry is scaling new heights amid an ongoing global tariff war.

5 mins

Designing Better Healthcare: By Women, For Women

Women's health is expected to see more focus in 2026 due to advancements in medical diagnostics, increased health education, and the rising demand for personalised care.

7 mins

Beyond the Glass Ceiling: Women-Led Companies Shaping India's Health Economy

Over the past decade, women entrepreneurs have gained strong ground in India's healthcare sector, building ventures in diagnostics, FemTech, biotech, and care delivery.

5 mins

Can Precision Oncology Deliver at Scale in India?

India has launched ambitious initiatives, from large-scale genome mapping to disease-specific genetic studies, to advance precision medicine. But with advanced diagnostic tests accessible to only about 5 per cent of the population, the question remains: is the country ready for precision care? Let's find out.

4 mins

"There needs to be a collaborative effort between innovators and policymakers to create frameworks that ensure safety without stifling progress"

Started in 2021, Decode Age, one of the pioneers in Longevity Research in India, entered its next phase of growth following its Pre-Series A funding round, led by Granules India.

5 mins

Telangana turns catalyst for innovation

Telangana is at a pivotal moment in its journey as a global life sciences hub.

6 mins

BioAsia 2026 Sets a New Benchmark for Global TechBio Collaboration

BioAsia 2026, the 23rd edition of Asia's premier life sciences and health-tech forum, concluded with unprecedented momentum in Hyderabad, firmly establishing the city's stature as a rising global epicentre for pharmaceuticals, biotechnology and TechBio innovation.

5 mins

ChemWerth on-boards Chandrakanth Reddy as new GSM to increase generic API footprint in India

US-based ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market.

1 mins

Haleon ropes in Kedar Lele as President for India Subcontinent

Haleon, a British multinational consumer healthcare company has announced the appointment of Kedar Lele as President for India Subcontinent (ISC), effective January 2026.

1 mins

Rainbow Children's Medicare appoints Abrarali Dalal as Chief Executive Officer

Rainbow Children's Medicare, a leading provider of paediatrics, perinatal, and women's healthcare services in India, has announced the appointment of Abrarali Dalal as Chief Executive Officer, effective from January 20, 2026.

1 mins

Is AI the New Weapon in the Fight to End TB?

A report released at the India AI Impact Summit 2026, organised by the Government of India, reveals that artificial intelligence (AI) is being successfully deployed at scale across India’s public healthcare system to address the growing burden of tuberculosis (TB).

2 mins

Lesen Sie alle Geschichten von Bio Spectrum

Bio Spectrum Description:

Herausgeber: MM-Activ-Sci-Tech-Communication

Kategorie: Business

Sprache: English

Frequenz: Monthly

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.